Skip to main content
OpenTrials
Completed

NCT Number: NCT02821624

First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers

This first-in-human (FIH) study will provide the first safety and pharmacokinetic (PK) data for G1T38 in humans and will allow further development of G1T38 in patients with cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

40 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

PRA Early Development Clinic

Groningen, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and female volunteers, 40-65 years of age; no clinically significant findings reported following detailed physical examination, medical history, vital signs, clinical laboratory tests, and ECGs as deemed by the PI
  • Body mass index (BMI) in the range of 18 to 32 kg/m2 (inclusive) at screening, and weighing at least 50 kg
  • Nonusers of nicotine-containing products for at least the previous 3 months prior to dosing or nonsmokers
  • Agreement to use birth control during the study and 3 months post last visit.
  • Able to comply with all protocol requirements and procedures

Exclusion criteria

  • Clinically significant abnormalities found during physical examinations, medical history review, ECGs (QTcF interval > 450 milliseconds for males and >470 milliseconds for females), vital signs, and laboratory tests (including positive HIV, hepatitis B and C)
  • Participated in in a previous clinical study with an investigational product in the last 60 days
  • History of any serious allergic reaction to any medication
  • Any blood or plasma donation or other loss of blood at a volume exceeding 500 mL within 3 months before dosing
  • History of drug or alcohol abuse in the last 2 years
  • Pregnant or lactating women
  • Any other issues which, in the opinion of the PI, will make the subject ineligible for study participation

Treatment and study plan

G1T38 (CDK 4/6 Inhibitor)

Drug

CDK 4/6 Inhibitor

Other names: G1T38

Placebo

Drug

Placebo

Primary outcomes

  1. Number of Treatment Related Adverse Event, including Abnormal Laboratory Events

    Time frame: Up to Day 7

    All AEs, including clinical laboratory, vitals signs, physical examinations and ECGs will be analyzed in all subjects receiving study drug through 7 days post dose of study drug.

Secondary outcomes

  1. Pharmacokinetics of G1T38: Maximum Plasma Concentration (Cmax)

    Time frame: Day 1, 2, 3, 4 and 5

    The observed peak plasma concentration determined from the plasma

  2. Pharmacokinetics of G1T38: Area under Curve - plasma concentration (AUC)

    Time frame: Day 1, 2, 3, 4 and 5

    Area under the plasma concentration-time curve

  3. Pharmacokinetics of G1T38: Plasma: terminal half life (T1/2)

    Time frame: Day 1, 2, 3, 4 and 5

    G1T38: Plasma- terminal half life (T1/2)

  4. Pharmacokinetics of G1T38: Plasma - Volume of distribution

    Time frame: Day 1, 2, 3, 4 and 5

    Volume of distribution in the terminal elimination phase

Sponsors and collaborators

Lead sponsor

G1 Therapeutics, Inc.

Industry

Registry information

Official study title

First-in-Human Phase 1 Safety, Pharmacokinetic, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Male and Female Subjects

Important dates

Study start
2016
Primary completion
2016
Study completion
2017
First posted
Jul 1, 2016
Registry last updated
Jun 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.